¼¼°èÀÇ Æú¸®Á¥»ê-±Û¸®ÄÝ»ê(PLGA) ½ÃÀå
Poly Lactic-co-Glycolic Acid (PLGA)
»óǰÄÚµå : 1773862
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 482 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,112,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,338,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Æú¸®Á¥»ê-±Û¸®ÄÝ»ê(PLGA) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3¾ï 4,920¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 3,690¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Æú¸®Á¥»ê-±Û¸®ÄÝ»ê(PLGA) ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 4,920¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °íÁ¥»ê µî±ÞÀº CAGR 18.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 5,570¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. °í±Û¸®ÄÝ»ê µî±Þ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 13.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,730¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 22.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Æú¸®Á¥»ê-±Û¸®ÄÝ»ê(PLGA) ½ÃÀåÀº 2024³â¿¡´Â 3,730¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 22.5%¸¦ ´õµë¾î, 2030³â±îÁö 7,780¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 12.4%¿Í 15.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 13.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Æú¸®Á¥»ê-±Û¸®ÄÝ»ê(PLGA) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

PLGA°¡ ¹ÙÀÌ¿À¸ÞµðÄà ¹× Á¦¾à ºÐ¾ß¿¡¼­ Á߿伺ÀÌ ³ô¾ÆÁö´Â ÀÌÀ¯

Æú¸®Á¥»ê-±Û¸®ÄÝ»ê(PLGA)Àº ¾à¹°Àü´Þ ½Ã½ºÅÛ, ÀÇ·á¿ë ÀÎÇöõÆ®, Á¶Á÷°øÇÐ, Àç»ýÀÇ·á µî¿¡ ³Î¸® »ç¿ëµÇ´Â »ýºÐÇØ¼º ¹× »ýüÀûÇÕ¼º °íºÐÀÚÀÔ´Ï´Ù. ¹«µ¶¼º ºÎ»ê¹°(Á¥»ê°ú ±Û¸®ÄÝ»ê)·Î ºÐÇØµÇ´Â ´É·ÂÀ¸·Î ÀÎÇØ ¾à¹° ¹æÃâ Á¦¾î, Èí¼ö¼º ºÀÇÕ»ç, Á¤Çü¿Ü°ú¿ë °íÁ¤ ÀåÄ¡, ³ª³ë/¹Ì¸³ÀÚ ±â¹Ý Ä¡·áÁ¦¿¡ ÀÌ»óÀûÀÎ ¼ÒÀçÀÔ´Ï´Ù.

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ »ýºÐÇØ¼º Æú¸®¸Ó¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â PLGA äÅÃÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ Áõ°¡, ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¶Á÷ Àç»ýÀÇ ¹ßÀüÀº Á¦¾à ¹× ¹ÙÀÌ¿À ÀÇ·á »ê¾÷¿¡¼­ PLGAÀÇ È°¿ëÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ FDA, À¯·´ÀǾàǰû(EMA) ¹× ±âŸ º¸°Ç ±â°üÀÇ ±ÔÁ¦ ½ÂÀÎÀº Â÷¼¼´ë ÀÇ·á ºÐ¾ß¿¡¼­ PLGAÀÇ ¿ªÇÒÀ» ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ PLGA´Â °íµµ·Î Á¶ÀýÀÌ °¡´ÉÇϱ⠶§¹®¿¡ °úÇÐÀÚµéÀº Á¥»ê(LA)°ú ±Û¸®ÄÝ»ê(GA)ÀÇ ºñÀ²À» Á¶Á¤ÇÏ¿© ºÐÇØ ¼Óµµ, ±â°èÀû Ư¼º ¹× ¾à¹° ¹æÃâ µ¿¿ªÇÐÀ» º¯°æÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯¿¬¼ºÀ¸·Î ÀÎÇØ ³ª³ëÀÔÀÚ, ºñ°è°øÇÐ, ¹ÙÀÌ¿À¼¾¼­, »ýüÈí¼ö¼º ÀÎÇöõÆ® µî¿¡ ³Î¸® ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù.

PLGA ±â¼úÀÇ Çõ½ÅÀº ¾î¶»°Ô ½ÃÀåÀÇ °¡´É¼ºÀ» ³ôÀ̰í Àִ°¡?

PLGA ½ÃÀåÀº ³ª³ë±â¼ú, ¸ÂÃãÇü ÀÇ·á, 3D ÇÁ¸°ÆÃ »ýüÀÇ·á Àç·áÀÇ ¹ßÀü°ú ÇÔ²² ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

°¡Àå Áß¿äÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â ¾à¹°Àü´ÞÀ» Á¦¾îÇϱâ À§ÇÑ PLGA ±â¹Ý ³ª³ëÀÔÀÚ ¹× ¸¶ÀÌÅ©·Î ÀÔÀÚÀÔ´Ï´Ù. ³ª³ëÀÔÀÚ ±â¹ÝÀÇ ¾à¹° ¿î¹Ýü´Â ¾à¹°ÀÇ ¾ÈÁ¤¼º, ¿ëÇØµµ, »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃÄÑ Áö¼ÓÀûÀÌ°í ±¹¼ÒÀûÀÎ ¾à¹° ¹æÃâÀ» °¡´ÉÇÏ°Ô Çϸç, PLGA ³ª³ëÀÔÀÚ´Â Á¾¾çÇÐ, À¯ÀüÀÚ Ä¡·á, ¹é½Å Àü´Þ, ½Å°æ ÅðÇ༺ Áúȯ Ä¡·á¿¡ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ¾î ÃÖ¼ÒÇÑÀÇ ºÎÀÛ¿ëÀ¸·Î Ç¥ÀûÈ­µÈ ¾à¹°Àü´ÞÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ç¥ÀûÈ­µÈ Àü´ÞÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿Í À¯ÀüÀÚ Ä¡·áÀÇ ¹ßÀüÀº Â÷¼¼´ë ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡¼­ PLGAÀÇ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °úÇÐÀÚµéÀº mRNA, CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý, ¸ÂÃãÇü ¾Ï Ä¡·á¸¦ À§ÇÑ PLGA ±â¹Ý ³ª³ë ij¸®¾î¸¦ ¼³°èÇÏ¿© Á¤¹Ð ÀÇ·á ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖÀ¸¸ç, mRNA ±â¹Ý ¹é½Å(¿¹ : COVID-19 ¹é½Å)ÀÇ ¼º°øÀº ¹Ì·¡ ¹é½Å Á¦Á¦¸¦ À§ÇÑ PLGA ±â¹Ý ÁöÁú ³ª³ëÀÔÀÚ(LNP) ´ë¾È¿¡ ´ëÇÑ ¿¬±¸¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÁöÁú ³ª³ëÀÔÀÚ(LNP) ´ëüÀç¿¡ ´ëÇÑ ¿¬±¸¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, 3D ÇÁ¸°ÆÃ PLGA ½ºÄ³ÆúµùÀº Á¶Á÷°øÇÐ ¹× Àç»ý ÀÇÇп¡ º¯È­¸¦ ÀÏÀ¸Å°°í ÀÖÀ¸¸ç, PLGAÀÇ »ýºÐÇØ¼º ¹× »ýüÈí¼ö¼º Ư¼ºÀº »À, ¿¬°ñ ¹× ¿¬Á¶Á÷ Àç»ý¿¡ ÀÌ»óÀûÀ̸ç, 3D ÇÁ¸°ÆÃµÈ PLGA »ýü Àç·á´Â ÇöÀç ¸ÂÃãÇü ÀÎÇöõÆ®, Á¤Çü¿Ü°ú¿ë À̽ÄÀç, ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ¾ÖÇø®ÄÉÀ̼ǿ¡ »ç¿ëµÇ¾î ÇÁ¸°ÆÃ ¾ÖÇø®ÄÉÀ̼ǿ¡ »ç¿ëµÇ¾î ȯÀÚ¸¦ À§ÇÑ ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼ÇÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

PLGA¿Í »ý¸®È°¼º ºÐÀÚ(¼ºÀåÀÎÀÚ, ÆéŸÀ̵å, ´Ü¹éÁú µî)¿ÍÀÇ ÅëÇÕÀº »óó Ä¡À¯, Ä¡°ú¿ë, ½Å°æ Àç»ý¿¡ À־ PLGAÀÇ ¿ªÇÒÀ» ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. °úÇÐÀÚµéÀº PLGA ±â¹Ý ÇÏÀ̵å·Î°Ö, ³ª³ë¼¶À¯, º¹ÇÕ »ýü Àç·á¸¦ ÷´Ü »óó µå·¹½Ì ¹× ¿Ü°ú ¼ö¼ú¿ëÀ¸·Î °³¹ßÇÏ¿© ȯÀÚÀÇ È¸º¹ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

PLGAÀÇ ¼ö¿ä°¡ ÇコÄÉ¾î ¹× ¹ÙÀÌ¿À¸ÞµðÄà ºÐ¾ß¿¡¼­ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Á¦¾à, ÀÇ·á±â±â, »ý¸í°øÇÐ »ê¾÷¿¡¼­ PLGAÀÇ »ç¿ëÀÌ Áõ°¡Çϸ鼭 ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, PLGAÀÇ Æ¯¼ºÀ¸·Î ÀÎÇØ ÇýÅÃÀ» ¹Þ´Â ÁÖ¿ä ºÐ¾ß´Â ´ÙÀ½°ú °°½À´Ï´Ù:

PLGA ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

PLGA ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, »ýºÐÇØ¼º ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀǾàǰ ¹× Àç»ýÀÇ·á ºÐ¾ß¿¡¼­ÀÇ ¿ëµµ È®´ë°¡ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

³ª³ë ÀÇ·á, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ, »ýü°øÇÐ ÀÎÇöõÆ® µîÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÊ¿¡ µû¶ó PLGA ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚ, Á¦¾à»ç, ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷ÀÌ »ýºÐÇØ¼º ¹× ȯÀÚ Ä£È­ÀûÀÎ ¼ÒÀ縦 ¼±È£ÇÏ´Â °¡¿îµ¥, PLGA´Â ¾à¹°Àü´Þ, Àç»ýÀÇ·á, ÷´Ü ÀÇ·á±â±â °³¹ßÀÇ ¹Ì·¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¶¼º(°íÁ¥»ê µî±Þ, °í±Û¸®ÄÝ»ê µî±Þ), °¡°ø¼º(¾ÐÃâ ¼ºÇü, »çÃâ ¼ºÇü, ±âŸ °¡°ø¼º), ¿ëµµ(ÀÇ·á ¿ëµµ, ºñÀÇ·á ¿ëµµ), ÃÖÁ¾ ¿ëµµ(ÇコÄɾî ÃÖÁ¾ ¿ëµµ, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, ÀÇ·á±â°ü ÃÖÁ¾ ¿ëµµ, Æ÷Àå ÃÖÁ¾ ¿ëµµ, ¼¶À¯ ÃÖÁ¾ ¿ëµµ, ³ó¾÷ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Poly Lactic-co-Glycolic Acid (PLGA) Market to Reach US$349.2 Million by 2030

The global market for Poly Lactic-co-Glycolic Acid (PLGA) estimated at US$136.9 Million in the year 2024, is expected to reach US$349.2 Million by 2030, growing at a CAGR of 16.9% over the analysis period 2024-2030. High Lactic Acid Grade, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$255.7 Million by the end of the analysis period. Growth in the High Glycolic Acid Grade segment is estimated at 13.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$37.3 Million While China is Forecast to Grow at 22.5% CAGR

The Poly Lactic-co-Glycolic Acid (PLGA) market in the U.S. is estimated at US$37.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$77.8 Million by the year 2030 trailing a CAGR of 22.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.4% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Global Poly (Lactic-co-Glycolic Acid) (PLGA) Market - Key Trends & Drivers Summarized

Why Is PLGA Gaining Importance in Biomedical and Pharmaceutical Applications?

Poly (Lactic-co-Glycolic Acid) (PLGA) is a biodegradable and biocompatible polymer widely used in drug delivery systems, medical implants, tissue engineering, and regenerative medicine. Its ability to degrade into non-toxic byproducts (lactic acid and glycolic acid) makes it an ideal material for controlled drug release, absorbable sutures, orthopedic fixation devices, and nano/microparticle-based therapeutics.

The rising demand for biodegradable polymers in healthcare is a key driver for PLGA’s adoption. The global burden of chronic diseases, increasing need for targeted drug delivery, and advancements in tissue regeneration have significantly boosted PLGA usage in pharmaceutical and biomedical industries. Regulatory approvals from the U.S. FDA, European Medicines Agency (EMA), and other health agencies have further solidified its role in next-generation medical treatments.

Additionally, PLGA is highly tunable, allowing scientists to modify its degradation rate, mechanical properties, and drug-release kinetics by adjusting the ratio of lactic acid (LA) to glycolic acid (GA). This flexibility has led to widespread applications in nanoparticles, scaffold engineering, biosensors, and bioresorbable implants.

How Are Innovations in PLGA Technology Enhancing Its Market Potential?

The PLGA market is evolving rapidly with advancements in nanotechnology, personalized medicine, and 3D-printed biomedical materials.

One of the most significant innovations is PLGA-based nanoparticles and microparticles for controlled drug delivery. Nanoparticle-based drug carriers improve drug stability, solubility, and bioavailability, allowing for sustained and localized drug release. PLGA nanoparticles are widely used in oncology, gene therapy, vaccine delivery, and neurodegenerative disease treatments, enabling targeted delivery with minimal side effects.

Personalized medicine and gene therapy advancements are also driving demand for PLGA in next-generation drug delivery systems. Scientists are engineering PLGA-based nanocarriers for mRNA, CRISPR-based gene editing, and personalized cancer treatments, offering precision medicine solutions. The success of mRNA-based vaccines (such as COVID-19 vaccines) has accelerated research into PLGA-based lipid nanoparticle (LNP) alternatives for future vaccine formulations.

Additionally, 3D-printed PLGA scaffolds are transforming tissue engineering and regenerative medicine. PLGA’s biodegradable and bioresorbable properties make it ideal for bone, cartilage, and soft tissue regeneration. 3D-printed PLGA biomaterials are now used in personalized implants, orthopedic grafts, and bioprinting applications, enabling customized medical solutions for patients.

The integration of PLGA with bioactive molecules (such as growth factors, peptides, and proteins) is further expanding its role in wound healing, dental applications, and nerve regeneration. Scientists are developing PLGA-based hydrogels, nanofibers, and composite biomaterials for advanced wound dressings and surgical applications, improving patient recovery outcomes.

Why Is Demand for PLGA Growing Across Healthcare and Biomedical Sectors?

The increasing use of PLGA across pharmaceutical, medical device, and biotechnology industries is driving market expansion. Key sectors benefiting from PLGA’s properties include:

What Factors Are Driving the Growth of the PLGA Market?

The growth in the PLGA market is driven by technological advancements, increasing demand for biodegradable medical solutions, and expanding applications in pharmaceuticals and regenerative medicine.

With ongoing innovations in nanomedicine, 3D bioprinting, and bioengineered implants, the PLGA market is set for rapid expansion. As healthcare providers, pharmaceutical companies, and biotech firms prioritize biodegradable and patient-friendly materials, PLGA will remain a key player in the future of drug delivery, regenerative medicine, and advanced medical device development.

SCOPE OF STUDY:

The report analyzes the Poly Lactic-co-Glycolic Acid (PLGA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Composition (High Lactic Acid Grade, High Glycolic Acid Grade); Processibility (Extrusion, Injection Molding, Other Processibilities); Application (Medical Application, Non-Medical Application); End-Use (Healthcare End-Use, Biotech Firms End-Use, Medical Institutions End-Use, Packaging End-Use, Textile End-Use, Agriculture End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â